RARE vs RGLD · rev $350.0M vs P/E 26, rev $919.7M
Ultragenyx (RARE) versus Royal Gold Inc (RGLD) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Royal Gold Inc (RGLD) is a gold company listed on NASDAQ.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported RGLD revenue for 2026-06-30 was $919.7M. Net income was $517.5M. Revenue was up 96.0% from 2026-03-31 to 2026-06-30. RGLD currently screens at market cap $18.54B and trailing P/E 26.4.
RARE currently screens at market cap $2.79B. RGLD currently screens at market cap $18.54B and trailing P/E 26.4.
Not investment advice. Open the RARE and RGLD stock pages for the full models.
Not investment advice.